•
Mar 31
Chemed Q1 2025 Earnings Report
Chemed reported strong Q1 2025 results with revenue growth led by VITAS and a solid EPS performance.
Key Takeaways
Chemed delivered solid Q1 2025 results, with revenue rising to $646.9M and adjusted EPS reaching $5.63. Growth was driven by VITAS Healthcare, bolstered by the recent Covenant Health acquisition, while Roto-Rooter remained relatively flat.
Chemed
Chemed
Chemed Revenue by Segment
Chemed Revenue by Geographic Location
Forward Guidance
Updated 2025 earnings guidance will be provided with the Q2 release in June.
Positive Outlook
- Strong revenue growth in VITAS segment driven by higher days-of-care.
- Successful integration of Covenant Health acquisition with meaningful revenue contribution.
- Improved adjusted EPS year-over-year.
- Healthy balance sheet with no current or long-term debt.
- Continued share repurchases indicating management confidence.
Challenges Ahead
- Roto-Rooter segment experienced flat growth and declining gross margins.
- Medicare Cap limitations continue to impact revenue.
- Decrease in net income for Roto-Rooter.
- SG&A expenses increased in both segments.
- Free cash flow declined significantly compared to prior year.